The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies

Christine Garcia; Kari L Ring

doi:10.1007/s11864-018-0593-2

The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies

Curr Treat Options Oncol. 2018 Nov 5;19(12):70. doi: 10.1007/s11864-018-0593-2.

Authors

Christine Garcia¹, Kari L Ring²

Affiliations

¹ Thorton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia, 1215 Lee Street, Charlottesville, VA, 22902, USA.
² Thorton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia, 1215 Lee Street, Charlottesville, VA, 22902, USA. Kel7j@virginia.edu.

PMID: 30397772
DOI: 10.1007/s11864-018-0593-2

Abstract

Activity of PD-1 and PD-L1 inhibitors has been demonstrated in ovarian, endometrial, and cervical cancer, with a tolerable side effect profile and the highest response rate seen in mismatch repair-deficient endometrial cancers. Other biomarkers are under active investigation. Tumor testing for mismatch repair deficiency or high microsatellite instability for treatment with pembrolizumab should be considered an option for all women with progressive gynecologic malignancy.

Keywords: Cervical cancer; Endometrial cancer; Gynecologic cancer; Immunotherapy; Ovarian cancer; Programmed death ligand-1.

Publication types

Review

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors*
Endometrial Neoplasms / drug therapy*
Female
Humans
Immunotherapy / methods
Microsatellite Instability / drug effects
Ovarian Neoplasms / drug therapy*
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
T-Lymphocytes, Cytotoxic / cytology
T-Lymphocytes, Cytotoxic / immunology
Uterine Cervical Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
Programmed Cell Death 1 Receptor
pembrolizumab